Jason S. Lewis
Radiochemist who built the zirconium-89 immuno-PET platform and MSKCC's radiopharmaceutical pipeline.
Overview
Jason Lewis developed methods for labelling antibodies with zirconium-89 that made immuno-PET a clinical reality, including 89Zr-trastuzumab and 89Zr-J591 PSMA imaging, and leads a laboratory translating new radiotracers and radioligand therapies from chemistry to first-in-human trials. He directs radiochemistry at MSKCC and has trained many of the field's leaders.
| Title | Journal | Year |
|---|---|---|
| 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo | Journal of Nuclear Medicine | 2010 |
| Immuno-PET of HER2-positive breast cancer with 89Zr-trastuzumab: a first-in-human study | Journal of Nuclear Medicine | 2016 |
Similar pages
not linked directly; found by shared links- TermTheranostic pair
Shares Zirconium-89 and the tags radiochemistry, theranostics.
- PersonNeeta Pandit-Taskar
Shares Memorial Sloan Kettering Cancer Center and the tag theranostics.
- IdeaCD8 PET to stop or switch immunotherapy early
Shares Immuno-PET, Zirconium-89.
- PersonJeremie Calais
Shares Journal of Nuclear Medicine, PSMA, Radioligand therapy (beta emitters).
- TermAntigen
- CompanyPrecirix
Shares HER2, Radioligand therapy (beta emitters).
- TargetHER3 (ERBB3)
Shares HER2, Zirconium-89.
- PersonWolfgang A. Weber
Shares Radioligand therapy (beta emitters) and the tag theranostics.